Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics (Nasdaq: PTIX) has secured a new Japanese patent (JP 7714571B) for its modified stilbenoid program drug candidates, valid until March 31, 2041. The patent covers compounds, formulations, and medical applications specifically targeting epilepsy and seizure treatments.
This development follows the previous grant of the same patent in the UK (Patent GB2609814). The company plans to pursue patent protection in additional territories to strengthen its development pipeline and intellectual property portfolio.
Protagenic Therapeutics (Nasdaq: PTIX) ha ottenuto un nuovo brevetto giapponese (JP 7714571B) per i suoi candidati farmaci della linea modificata di stilbenoidi, valido fino al 31 marzo 2041. Il brevetto copre composti, formulazioni e applicazioni mediche specificamente rivolte al trattamento dell'epilessia e delle crisi convulsive.
Questo sviluppo segue la precedente concessione dello stesso brevetto nel Regno Unito (Brevetto GB2609814). L'azienda intende estendere la protezione brevettuale in ulteriori territori per rafforzare la propria pipeline di sviluppo e il portafoglio di propriet脿 intellettuale.
Protagenic Therapeutics (Nasdaq: PTIX) ha asegurado una nueva patente japonesa (JP 7714571B) para sus candidatos a f谩rmacos modificados de stilbenoides, v谩lida hasta el 31 de marzo de 2041. La patente cubre compuestos, formulaciones y aplicaciones m茅dicas espec铆ficamente dirigidas al tratamiento de la epilepsia y las convulsiones.
Este avance sigue a la concesi贸n previa de la misma patente en el Reino Unido (Patente GB2609814). La empresa planea buscar protecci贸n de patente en otros territorios para fortalecer su cartera de desarrollo y propiedad intelectual.
Protagenic Therapeutics (雮橃姢雼�: PTIX)臧� 靾橃爼霅� 鞀ろ嫺氩� 頇旐暕氍� 頂勲攴鸽灗 頉勲炒 鞎诫鞐� 雽�頃� 靸堧鞖� 鞚茧掣 韸鬼棃(JP 7714571B)毳� 須嶋摑頄堨溂氅�, 鞚措姅 2041雲� 3鞗� 31鞚�旯岇 鞙犿毃頃╇媹雼�. 鞚� 韸鬼棃電� 臧勳 氚� 氚滌瀾 旃橂毳� 氇╉憸搿� 頃橂姅 頇旐暕氍�, 鞝滍槙 氚� 鞚橂 鞝侅毄鞚� 韽暔頃╇媹雼�.
鞚措矆 韸鬼棃 須嶋摑鞚� 鞓侁淡鞐愳劀 霃欖澕頃� 韸鬼棃(韸鬼棃 GB2609814)毳� 氚涭潃 雿� 鞚挫潃 瓴冹瀰雼堧嫟. 須岇偓電� 臧滊皽 韺岇澊頂勲澕鞚戈臣 歆�鞝� 鞛偘甓� 韽姼韽措Μ鞓るゼ 臧曧檾頃橁赴 鞙勴暣 於旉皜 歆�鞐棎靹� 韸鬼棃 氤错樃毳� 於旍頃� 瓿勴殟鞛呺媹雼�.
Protagenic Therapeutics (Nasdaq : PTIX) a obtenu un nouveau brevet japonais (JP 7714571B) pour ses candidats m茅dicaments modifi茅s 脿 base de stilb猫nes, valable jusqu'au 31 mars 2041. Le brevet couvre des compos茅s, des formulations et des applications m茅dicales ciblant sp茅cifiquement l'茅pilepsie et le traitement des crises.
Cette avanc茅e fait suite 脿 l'octroi ant茅rieur du m锚me brevet au Royaume-Uni (Brevet GB2609814). L'entreprise pr茅voit de poursuivre la protection par brevet dans d'autres territoires afin de renforcer son pipeline de d茅veloppement et son portefeuille de propri茅t茅 intellectuelle.
Protagenic Therapeutics (Nasdaq: PTIX) hat ein neues japanisches Patent (JP 7714571B) f眉r seine modifizierten Stilbenoid-Programmkandidaten erhalten, g眉ltig bis zum 31. M盲rz 2041. Das Patent umfasst Verbindungen, Formulierungen und medizinische Anwendungen, die speziell auf Epilepsie und Anfallbehandlungen abzielen.
Diese Entwicklung folgt der vorherigen Erteilung desselben Patents im Vereinigten K枚nigreich (Patent GB2609814). Das Unternehmen plant, den Patentschutz in weiteren Regionen zu verfolgen, um seine Entwicklungspipeline und sein geistiges Eigentum zu st盲rken.
- Patent protection in Japan secured until 2041 for epilepsy and seizure treatment compounds
- Expansion of intellectual property portfolio with previous UK patent grant
- Strategic protection of key pipeline assets in major markets
- None.
NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the 鈥淐ompany鈥�) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of the Company鈥檚 key pipeline assets, a modified stilbenoid, and importantly provides the Company with exclusivity to particular compounds per se, formulations containing a number of drug candidates, and their medical use, which is to treat epilepsy and seizures.
Colin Stott, Chief Operating Officer of Protagenic Therapeutics, Inc. said:
鈥淲e are delighted to announce the grant of this important patent for the Company in Japan. Such a grant builds on the previous grant of the same patent in the UK (Patent GB2609814), and demonstrates the ability of the Company to continue its innovative approach and to add value and important protection to its development pipeline for shareholders. We anticipate applying to expand the grant of this patent in other territories in the future.鈥�
About the Japanese Pharmaceutical Market1,2
The Japanese pharmaceutical market is the world鈥檚 third largest pharmaceutical market. In 2025, the Japanese pharmaceutical market is worth more than
About the Global Epilepsy Drug Market3
The global epilepsy drug market size was expected to be valued at USD
References
- 1)
- 2)
- 3)
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics (Nasdaq: PTIX) is pioneering novel treatments across a range of therapeutic areas. For more information, visit聽.
Forward-Looking Statements
Statements in this press release contain 鈥渇orward-looking statements,鈥� within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渟eek,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟uggest,鈥� 鈥渢arget,鈥� 鈥渁im,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company鈥檚 current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to the Company鈥檚 product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 鈥淩isk Factors鈥� in the Company鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Company Contact:
Alexander K. Arrow, MD, CFA
Chief Financial Officer
Protagenic Therapeutics, Inc.
149 Fifth Ave, Suite 500, New York, NY 10010
Tel: 213-260-4342
贰尘补颈濒:听
FAQ
What patent did Protagenic Therapeutics (PTIX) receive in Japan?
When does Protagenic Therapeutics' new Japanese patent expire?
What medical conditions does PTIX's newly patented technology target?
In which countries does Protagenic Therapeutics now hold patents for its modified stilbenoid program?
What is the significance of PTIX's Japanese patent grant?
